Performance evaluation of a novel chemiluminescence assay for detection of anti-GBM antibodies: an international multicenter study

Abstract

The novel QUANTA Flash™ GBM CIA demonstrated good sensitivity and specificity and had good agreement with other methods. Our data confirm that ∼5% of patients with GPS do not have detectable levels of anti-GBM antibodies.